RecruitingPhase 3NCT06970743
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study Director Study DirectorBeOne Medicines
- Intervention
- BGB-16673(drug)
- Enrollment
- 150 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Peking University Peoples Hospital, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Chongqing University Three Gorges Central Hospital, Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Sun Yat Sen University Cancer Centerhuangpu Branch, Guangzhou, Guangdong, China
- Meizhou People Hospital, Meizhou, Guangdong, China
- Shenzhen Nanshan Peoples Hospital, Shenzhen, Guangdong, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Red Cross Hospital of Yulin City, Yulin, Guangxi, China
- Guizhou Provincial Peoples Hospital, Guiyang, Guizhou, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06970743 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn